Navigation Links
Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
Date:5/8/2008

, BC, Canada.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards, Edwards SAPIEN, FemTrak, OptiSite and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Ascendra, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna, Carpentier-Edwards Physio and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
2. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
3. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
6. Edwards Lifesciences Forecasts Strong Growth in 2008
7. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
8. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
9. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
10. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Edwards Lifesciences Announces Organizational Changes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker.c...available in its catalogue: ,, Industrial Enzy...portlinker.com/p0164431/Industrial-Enzymes---A-Glo...arket is an oligopoly with few strong players and ...activities. Keen competition and commoditization c...
(Date:12/1/2009)...MOUTH, Mass., Dec. 1 Harvest Techn...day results from the company sponsored 60-patient ...l Center in Chennai, India using the company,s BMA...e Critical Limb Ischemia (CLI). Sri Ramachandra Me...sociated institution based in Chennai, India and o...
(Date:12/1/2009)... Former Majority Leader Richard Gephardt Brings T..., Biotech Communities for "Best and Brightest For...., Dec. 1 Several of Ne...icals, research, medicine and technology gathered ... importance of medical innovation in New Jersey, a...
(Date:12/1/2009)...ARASOTA, Fla., Dec. 1 Expanding it...otechnics Inc. of Sarasota has appointed Lake Chem..., Lake is located near Birmingham, England. ,... which serve the agricultural, waste water, and en...ungry and to open drain fields, and clean up indus...
Breaking Biology Technology:Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5
...rned another national mention as a "biotech hotspo...In aggregate this kind of recognition raises the s...ry has been asking for. , ,Joining Wisconsin on th... New Jersey and Singapore. John Carroll, the edito...it was a subjective ranking based on "chemistry as...
... GE Healthcare Technologies in Waukesha has a ne...ief executive Reinoldo Garcia will be moving on to..., ,Mark Vachon, who was executive vice president a...CEO. He has held many roles with the company, incl...subsidiary. , , GE Healthcare is a far-flung comp...
...ation Center Back in the mid-1980s, encouraging e...st Wisconsin public utilities. But then Plant Site...h business concentrations across the U.S. , ,Jim ...adison Gas & Electric, saw the article and mention... County had more high-tech development than the ma...
Other Biology Technology:Utilities help switch on economic development 2Utilities help switch on economic development 3Utilities help switch on economic development 4
(Date:12/2/2009)...D SHORES, Calif. and PALM HARBOR, Fla., Dec. 2 /PR...Corporation ("CIC") (OTC Bulletin Board: CICI), a ... for business process automation in the financial ... signature verification and Docubase Systems Inc. ...ocument Management (EDM) software provider announc...
(Date:12/2/2009)...nt at the University of Southampton,s School of Oc...ography Centre, Southampton (NOCS) has formally de...e deep sea. , Hall discovered the new species in...m of Natural History in Washington. Explaining the...nclude some of the largest crustaceans currently i...
(Date:12/1/2009)...Calif., Dec. 1 GestureTek Inc. tod... a turnkey, portable, plug and play interactive pr... entertainment and touring promotions. GestureTek ... camera-enabled gesture recognition technology for...nt systems. ,, Guaranteed for quality, the CUBE...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4King crab family bigger than ever 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 52086 1Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 52086 2Advance Research Associates Joins DATATRAKs CRO Connect Program 28TM 29 52083 1Advance Research Associates Joins DATATRAKs CRO Connect Program 28TM 29 52083 2Advance Research Associates Joins DATATRAKs CRO Connect Program 28TM 29 52083 3Advance Research Associates Joins DATATRAKs CRO Connect Program 28TM 29 52083 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9
...nto researchers have uncovered the basis by which ...and have also discovered how the HIV virus works t... to improved vaccines for pregnant women in malari...se spread by mosquitoes that kills more than one m...s mostly children, malaria also severely affects p...
...ted by researchers from the University of Verona a...irms the pivotal role played by Cytomegalovirus in...Atherosclerosis is the main cause of morbidity and...ng smoking, diabetes, hypertension and high choles...he pathogenesis of the disease that also recognise...
...otic drug used in emergency rooms to treat methamp...f the brain known to regulate movement, a new stud...with rats, indicate that only the combination of t...uses the destructive effects, not either one alone...at Boston University School of Medicine suspect th...
Other Biology News:HIV and malaria combine to adversely affect pregnant women and their infants 2Cytomegalovirus exacerbates atherosclerosis through an autoimmune mechanism 2Common treatment for methamphetamine overdose may damage brain cells 2
Rat PTX2 / SAP, Unconjugated from R&D Systems
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)
Feline IL-5, Unconjugated from R&D Systems
Biology Products: